Seneszenter

Seneszenter is the term used to describe cells that have entered cellular senescence, a stable state of cell cycle arrest in which cells no longer divide in response to damage or stress. Seneszenter cells remain metabolically active and often secrete a broad spectrum of factors collectively known as the senescence-associated secretory phenotype (SASP).

Seneszenter arise from various triggers, including telomere shortening, DNA damage, oxidative stress, oncogene activation, and chronic inflammation. They are typically characterized by markers such as p16INK4A and p21, persistent DNA damage foci, and increased activity of senescence-associated beta-galactosidase under specific assay conditions. The SASP includes inflammatory cytokines, growth factors, and proteases that can influence neighboring cells and tissue structure.

In aging and disease, seneszenter play dual roles. They help suppress tumor formation and contribute to wound healing and embryonic development, but their accumulation over time and persistent SASP can promote chronic inflammation, tissue dysfunction, and the progression of age-related diseases such as osteoarthritis, atherosclerosis, and neurodegenerative conditions. The context and duration of senescence determine whether the effects are beneficial or detrimental.

Detection and study of seneszenter rely on biomarkers such as SA-β-gal activity, p16 expression, and DNA damage indicators, often in combination with transcriptional and proteomic profiles. Therapeutic approaches aim to mitigate harm from seneszenter by clearing them with senolytics or by modulating the SASP with senomorphics. Research explores efficacy, safety, and precision in targeting these cells across tissues.